Valence8 Us LP Apellis Pharmaceuticals, Inc. Call Options Transaction History
Valence8 Us LP
- $241 Billion
- Q3 2024
Call Options
1 transactions
Others Institutions Holding APLS
# of Institutions
308Shares Held
115MCall Options Held
3.85MPut Options Held
1.09M-
Wellington Management Group LLP Boston, MA15.6MShares$409 Million0.08% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$312 Million14.88% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.1MShares$292 Million4.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.82MShares$258 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.8MShares$152 Million0.01% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.89B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...